A citation-based method for searching scientific literature

Daniel R Principe, Patrick W Underwood, Sandeep Kumar, Kaytlin E Timbers, Regina M Koch, Jose G Trevino, Hidayatullah G Munshi, Ajay Rana. Front Oncol 2022
Times Cited: 4







List of co-cited articles
8 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


XP-524 is a dual-BET/EP300 inhibitor that represses oncogenic KRAS and potentiates immune checkpoint inhibition in pancreatic cancer.
Daniel R Principe, Rui Xiong, Yangfeng Li, Thao N D Pham, Suneel D Kamath, Oleksii Dubrovskyi, Kiira Ratia, Fei Huang, Jiong Zhao, Zhengnan Shen,[...]. Proc Natl Acad Sci U S A 2022
4
100

Long-Term Gemcitabine Treatment Reshapes the Pancreatic Tumor Microenvironment and Sensitizes Murine Carcinoma to Combination Immunotherapy.
Daniel R Principe, Matthew Narbutis, Sandeep Kumar, Alex Park, Navin Viswakarma, Matthew J Dorman, Suneel D Kamath, Paul J Grippo, Melissa L Fishel, Rosa F Hwang,[...]. Cancer Res 2020
45
100

NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
Andrea Wang-Gillam, Richard A Hubner, Jens T Siveke, Daniel D Von Hoff, Bruce Belanger, Floris A de Jong, Beloo Mirakhur, Li-Tzong Chen. Eur J Cancer 2019
84
50

Metastatic Pancreatic Cancer: American Society of Clinical Oncology Clinical Practice Guideline Summary.
Davendra P S Sohal, Pamela B Mangu, Daniel Laheru. J Oncol Pract 2017
17
50

The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy.
Daniel R Principe, Patrick W Underwood, Murray Korc, Jose G Trevino, Hidayatullah G Munshi, Ajay Rana. Front Oncol 2021
14
50


TGFβ Blockade Augments PD-1 Inhibition to Promote T-Cell-Mediated Regression of Pancreatic Cancer.
Daniel R Principe, Alex Park, Matthew J Dorman, Sandeep Kumar, Navin Viswakarma, Jonathan Rubin, Carolina Torres, Ronald McKinney, Hidayatullah G Munshi, Paul J Grippo,[...]. Mol Cancer Ther 2019
65
50

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020
768
50

The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Andrew J Wilson, Matthew Stubbs, Phillip Liu, Bruce Ruggeri, Dineo Khabele. Gynecol Oncol 2018
57
25

Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition.
Diar Aziz, Neil Portman, Kristine J Fernandez, Christine Lee, Sarah Alexandrou, Alba Llop-Guevara, Zoe Phan, Aliza Yong, Ashleigh Wilkinson, C Marcelo Sergio,[...]. NPJ Breast Cancer 2021
4
25

Epigenetic treatment of pancreatic cancer: is there a therapeutic perspective on the horizon?
Elisabeth Hessmann, Steven A Johnsen, Jens T Siveke, Volker Ellenrieder. Gut 2017
74
25

ATM Deficiency Generating Genomic Instability Sensitizes Pancreatic Ductal Adenocarcinoma Cells to Therapy-Induced DNA Damage.
Lukas Perkhofer, Anna Schmitt, Maria Carolina Romero Carrasco, Michaela Ihle, Stephanie Hampp, Dietrich Alexander Ruess, Elisabeth Hessmann, Ronan Russell, André Lechel, Ninel Azoitei,[...]. Cancer Res 2017
63
25

Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors.
Yi Du, Hirohito Yamaguchi, Yongkun Wei, Jennifer L Hsu, Hung-Ling Wang, Yi-Hsin Hsu, Wan-Chi Lin, Wen-Hsuan Yu, Paul G Leonard, Gilbert R Lee,[...]. Nat Med 2016
142
25

Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma.
Robert R McWilliams, Kari G Rabe, Curtis Olswold, Mariza De Andrade, Gloria M Petersen. Cancer 2005
62
25

FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA Mutation-Associated Advanced Ovarian Cancer.
Sanjeeve Balasubramaniam, Julia A Beaver, Sara Horton, Laura L Fernandes, Shenghui Tang, Hisani N Horne, Jinzhong Liu, Chao Liu, Sarah J Schrieber, Jingyu Yu,[...]. Clin Cancer Res 2017
87
25

Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer.
Jason P W Carey, Cansu Karakas, Tuyen Bui, Xian Chen, Smruthi Vijayaraghavan, Yang Zhao, Jing Wang, Keith Mikule, Jennifer K Litton, Kelly K Hunt,[...]. Cancer Res 2018
69
25

Germline BRCA Mutations in a Large Clinic-Based Cohort of Patients With Pancreatic Adenocarcinoma.
Spring Holter, Ayelet Borgida, Anna Dodd, Robert Grant, Kara Semotiuk, David Hedley, Neesha Dhani, Steven Narod, Mohammad Akbari, Malcolm Moore,[...]. J Clin Oncol 2015
229
25

Single-Arm Phases 1 and 2 Trial of Niraparib in Combination With Pembrolizumab in Patients With Recurrent Platinum-Resistant Ovarian Carcinoma.
Panagiotis A Konstantinopoulos, Steven Waggoner, Gregory A Vidal, Monica Mita, John W Moroney, Robert Holloway, Linda Van Le, Jasgit C Sachdev, Eloise Chapman-Davis, Gerardo Colon-Otero,[...]. JAMA Oncol 2019
194
25

ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cells.
Stephanie A Yazinski, Valentine Comaills, Rémi Buisson, Marie-Michelle Genois, Hai Dang Nguyen, Chu Kwen Ho, Tanya Todorova Kwan, Robert Morris, Sam Lauffer, André Nussenzweig,[...]. Genes Dev 2017
202
25

Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis.
Raffaella Casolino, Salvatore Paiella, Danila Azzolina, Philip A Beer, Vincenzo Corbo, Giulia Lorenzoni, Dario Gregori, Talia Golan, Chiara Braconi, Fieke E M Froeling,[...]. J Clin Oncol 2021
20
25

Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells.
Aki Miyasaka, Katsutoshi Oda, Yuji Ikeda, Osamu Wada-Hiraike, Tomoko Kashiyama, Atsushi Enomoto, Noriko Hosoya, Takahiro Koso, Tomohiko Fukuda, Kanako Inaba,[...]. BMC Cancer 2014
44
25

BET bromodomain inhibition as a therapeutic strategy to target c-Myc.
Jake E Delmore, Ghayas C Issa, Madeleine E Lemieux, Peter B Rahl, Junwei Shi, Hannah M Jacobs, Efstathios Kastritis, Timothy Gilpatrick, Ronald M Paranal, Jun Qi,[...]. Cell 2011
25

Population-Based Genetic Testing for BRCA1 and BRCA2.
Steven Narod, Mohammad R Akbari. J Clin Oncol 2018
5
25

Glycogen synthase kinase 3β inhibition synergizes with PARP inhibitors through the induction of homologous recombination deficiency in colorectal cancer.
Ning Zhang, Yu-Nan Tian, Li-Na Zhou, Meng-Zhu Li, Hua-Dong Chen, Shan-Shan Song, Xia-Juan Huan, Xu-Bin Bao, Ao Zhang, Ze-Hong Miao,[...]. Cell Death Dis 2021
5
25

A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Joyce F Liu, Sara M Tolaney, Michael Birrer, Gini F Fleming, Mary K Buss, Suzanne E Dahlberg, Hang Lee, Christin Whalen, Karin Tyburski, Eric Winer,[...]. Eur J Cancer 2013
115
25


The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
Gordon T Moffat, Eileen M O'Reilly. Clin Adv Hematol Oncol 2020
5
25


PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: implications for radiotherapy and chemotherapy.
Michael Fraser, Helen Zhao, Kaisa R Luoto, Cecilia Lundin, Carla Coackley, Norman Chan, Anthony M Joshua, Tarek A Bismar, Andrew Evans, Thomas Helleday,[...]. Clin Cancer Res 2012
97
25

An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
Nicholas Pulliam, Fang Fang, Ali R Ozes, Jessica Tang, Adeoluwa Adewuyi, Harold Keer, John Lyons, Stephen B Baylin, Daniela Matei, Harikrishna Nakshatri,[...]. Clin Cancer Res 2018
63
25

Role of BRCA Mutations in the Modulation of Response to Platinum Therapy.
Sanghamitra Mylavarapu, Asmita Das, Monideepa Roy. Front Oncol 2018
61
25

A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery.
Kenichi Iwai, Tadahiro Nambu, Yukie Kashima, Jie Yu, Kurt Eng, Kazumasa Miyamoto, Kazuyo Kakoi, Masamitsu Gotou, Toshiyuki Takeuchi, Akifumi Kogame,[...]. Sci Adv 2021
2
50

Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma.
Jian-Fang Ning, Monica Stanciu, Melissa R Humphrey, Joshua Gorham, Hiroko Wakimoto, Reiko Nishihara, Jacqueline Lees, Lee Zou, Robert L Martuza, Hiroaki Wakimoto,[...]. Nat Commun 2019
50
25

Selective inhibition of BET bromodomains.
Panagis Filippakopoulos, Jun Qi, Sarah Picaud, Yao Shen, William B Smith, Oleg Fedorov, Elizabeth M Morse, Tracey Keates, Tyler T Hickman, Ildiko Felletar,[...]. Nature 2010
25

DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.
Rachel Abbotts, Michael J Topper, Christopher Biondi, Daniel Fontaine, Reena Goswami, Lora Stojanovic, Eun Yong Choi, Lena McLaughlin, Aksinija A Kogan, Limin Xia,[...]. Proc Natl Acad Sci U S A 2019
38
25

Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.
Maeve A Lowery, Winston Wong, Emmet J Jordan, Jonathan W Lee, Yelena Kemel, Joseph Vijai, Diana Mandelker, Ahmet Zehir, Marinela Capanu, Erin Salo-Mullen,[...]. J Natl Cancer Inst 2018
108
25

Olaparib.
Sylvia Bochum, Stephanie Berger, Uwe M Martens. Recent Results Cancer Res 2018
28
25

PARP Inhibition Increases the Reliance on ATR/CHK1 Checkpoint Signaling Leading to Synthetic Lethality-An Alternative Treatment Strategy for Epithelial Ovarian Cancer Cells Independent from HR Effectiveness.
Patrycja Gralewska, Arkadiusz Gajek, Agnieszka Marczak, Michał Mikuła, Jerzy Ostrowski, Agnieszka Śliwińska, Aneta Rogalska. Int J Mol Sci 2020
7
25

Liposomal irinotecan and 5-fluorouracil/leucovorin in older patients with metastatic pancreatic cancer - A subgroup analysis of the pivotal NAPOLI-1 trial.
Teresa Macarulla, Jean-Frédéric Blanc, Andrea Wang-Gillam, Li-Tzong Chen, Jens T Siveke, Beloo Mirakhur, Jie Chen, Floris A de Jong. J Geriatr Oncol 2019
9
25

Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas.
Kathryn P Pennington, Tom Walsh, Maria I Harrell, Ming K Lee, Christopher C Pennil, Mara H Rendi, Anne Thornton, Barbara M Norquist, Silvia Casadei, Alexander S Nord,[...]. Clin Cancer Res 2014
562
25

HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.
Shanthi Adimoolam, Mint Sirisawad, Jun Chen, Patti Thiemann, James M Ford, Joseph J Buggy. Proc Natl Acad Sci U S A 2007
176
25

Bromodomain: an acetyl-lysine binding domain.
Lei Zeng, Ming Ming Zhou. FEBS Lett 2002
520
25

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
25


Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Melinda L Telli, Kirsten M Timms, Julia Reid, Bryan Hennessy, Gordon B Mills, Kristin C Jensen, Zoltan Szallasi, William T Barry, Eric P Winer, Nadine M Tung,[...]. Clin Cancer Res 2016
438
25

A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer.
Michael J Pishvaian, Hongkun Wang, Aiwu Ruth He, Jimmy J Hwang, Brandon G Smaglo, Sunnie S Kim, Benjamin A Weinberg, Louis M Weiner, John L Marshall, Jonathan R Brody. Clin Cancer Res 2020
21
25

Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Kyungsoo Ha, Warren Fiskus, Dong Soon Choi, Srividya Bhaskara, Leandro Cerchietti, Santhana G T Devaraj, Bhavin Shah, Sunil Sharma, Jenny C Chang, Ari M Melnick,[...]. Oncotarget 2014
101
25

Synergistic inhibition of pancreatic cancer with anti-PD-L1 and c-Myc inhibitor JQ1.
Yu Pan, Qinglin Fei, Ping Xiong, Jianyang Yang, Zheyang Zhang, Xianchao Lin, Minggui Pan, Fengchun Lu, Heguang Huang. Oncoimmunology 2019
30
25

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance.
Diana Zatreanu, Helen M R Robinson, Omar Alkhatib, Marie Boursier, Harry Finch, Lerin Geo, Diego Grande, Vera Grinkevich, Robert A Heald, Sophie Langdon,[...]. Nat Commun 2021
32
25

Homologous recombination deficiency in ovarian cancer: a review of its epidemiology and management.
Renata Rodrigues da Cunha Colombo Bonadio, Rodrigo Nogueira Fogace, Vanessa Costa Miranda, Maria Del Pilar Estevez Diz. Clinics (Sao Paulo) 2018
50
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.